The effect of diclofenac sodium on bladder detrusor contractility and its clinical implication

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61:37-49.10.1016/S0090-4295(02)02243-4Open DOISearch in Google Scholar

2. MacDiarmid S, Sandage BW, Jr., Malhotra BK. The effects of reformulation: improved therapeutic index. Curr Urol Rep. 2008; 9:465-71.10.1007/s11934-008-0080-618947511Open DOISearch in Google Scholar

3. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10:283-9.10.1007/s00192997000310543335Open DOISearch in Google Scholar

4. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995; 44: 423-33.10.1007/BF017576998564518Open DOISearch in Google Scholar

5. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999; 128:1121-32.10.1038/sj.bjp.0702897157174410578123Open DOISearch in Google Scholar

6. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/ Sumatriptan Migraine Study Group. Cephalalgia. 1999; 19:232-40.10.1046/j.1468-2982.1999.019004232.x10376168Search in Google Scholar

7. McNeely W, Goa KL. Diclofenac-potassium in migraine: a review. Drugs. 1999; 57:991-1003.10.2165/00003495-199957060-0001610400409Open DOISearch in Google Scholar

8. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache. 1992; 32:98-100.10.1111/j.1526-4610.1992.hed3202098.x1551795Open DOISearch in Google Scholar

9. Kuznetsova AA, Shakhmatova EI, Prutskova NP, Natochin YV. Possible role of prostaglandins in pathogenesis of nocturnal enuresis in children. Scand J Urol Nephrol. 2000; 34:27-31.10.1080/00365590075001684110757266Open DOISearch in Google Scholar

10. Davenport K, Timoney AG, Keeley FX, Jr. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res. 2007; 35:207-13.10.1007/s00240-007-0100-x17530238Open DOISearch in Google Scholar

11. Chaignat V, Danuser H, Stoffel MH, Z’brun S, Studer UE, Mevissen M. Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol. 2008; 154:1297-307.10.1038/bjp.2008.193Open DOISearch in Google Scholar

12. Badawi JK, Li H, Langbein S, Kwon ST, Kamp S, Bross S. Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle. Eur J Clin Pharmacol. 2006; 62:347-54.10.1007/s00228-006-0100-8Open DOISearch in Google Scholar

13. Roosen A, Wu C, Sui G, Chowdhury RA, Patel PM, Fry CH. Characteristics of spontaneous activity in the bladder trigone. Eur Urol. 2009; 56:346-53.10.1016/j.eururo.2008.06.048Open DOISearch in Google Scholar

14. Batislam E, Nuhoglu B, Peskircioglu L, Emir L, Uygur C, Germiyanoglu C, et al. A prostaglandin synthesis inhibitor, diclofenac sodium in the treatment of primary nocturnal enuresis. Acta Urol Belg. 1995; 63:35-8.Search in Google Scholar

15. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009; 63:1177-91.10.1111/j.1742-1241.2009.02078.xOpen DOISearch in Google Scholar

16. Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999; 84: 923-47.10.1046/j.1464-410x.1999.00397.xOpen DOISearch in Google Scholar

17. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003; 326:841-4.10.1136/bmj.326.7394.841Open DOISearch in Google Scholar

18. Roshani A, Falahatkar S, Khosropanah I, Roshan ZA, Zarkami T, Palizkar M, et al. Assessment of clinical efficacy of intranasal desmopressin spray and diclofenac sodium suppository in treatment of renal colic versus diclofenac sodium alone. Urology. 2010; 75:540-2.10.1016/j.urology.2008.05.053Open DOISearch in Google Scholar

19. Iselin CE, Alm P, Schaad NC, Larsson B, Graber P, Andersson KE. Nitric oxide inhibits contraction of isolated pig ureteral smooth muscle. J Urol. 1996; 155: 763-7.10.1016/S0022-5347(01)66517-0Open DOISearch in Google Scholar

20. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87:760-6.10.1046/j.1464-410x.2001.02228.x11412210Open DOISearch in Google Scholar

21. Stewart W, Herzog R, Wein A. The prevalence and impact of overactive bladder in the U.S.: results from the NOBLE program. Neurourol Urodyn. 2001; 20: 406-8.Search in Google Scholar

22. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20:327-3610.1007/s00345-002-0301-412811491Search in Google Scholar